IJCS | Volume 33, Nº3, May / June 2020

1. Brasil. Ministério da Saúde. Saúde Brasil 2018 uma análise de situação de saúde e das doenças e agravos crônicos: desafios e perspectivas. Brasília; 2019. 2. Farias MR, Leite SN, Tavares NUL,Oliveira MA, Arrais PS, Bertoldi AD, et al. et al. Use and access to oral and injectable contraceptives in Brazil. Rev Saude Publica 2016; 50:14s. 3. Torgrimson BN, Meendering JR, Kaplan PF, Minson CT. Endothelial function across an oral contraceptive cycle inwomen using levonorgestrel and ethinyl estradiol. Am J Physiol Heart Circ Physiol. 2007; 292(6):H2874-80. 4. Lalude OO. Risk of cardiovascular events with hormonal contraception: insights from the Danish cohort study. Curr Cardiol Rep. 2013;15(7):374. 5. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009;53(3):221-31. 6. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201-10. 7. Liu H, Yao J, Wang W,Zhang D. Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis. J Clin Hypertens (Greenwich). 2017;19(10):1032-41. 8. Chen JT, Kotani K. Oral contraceptive therapy increases oxidative stress in pre-menopausal women. Int J Prev Med. 2012;3(12):893-6. 9. Olatunji LA, Seok YM, Igunnu A. Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(1):14&-57. 389(1):1147-57. 10. Oliveira SS, Petto J, Diogo DP, Santos AC, Sacramento MS, LadeiaAMT, et al. Plasma Renin in Women Using and Not Using Combined Oral Contraceptive. Int J Cardiovasc Sci. 2020;33(3):208-214. References 216 Kasal & Lorenzo Oral contraceptives and cardiovascular risk Int J Cardiovasc Sci. 2020; 33(3):215-216 Editorial This is an open-access article distributed under the terms of the Creative Commons Attribution License